5 Key Takeaways

• 1

  The FIND-CKD trial included 903 participants with glomerular diseases, assessing the effects of finerenone versus placebo.

• 2

  Finerenone reduced the eGFR decline by 1.22 mL/min/1.73 m² per year after 3 months compared to placebo.

• 3

  In the immunoglobulin A nephropathy subgroup, finerenone decreased urinary albumin-to-creatinine ratio by 47%.

• 4

  Serious adverse events were similar between finerenone (20%) and placebo (21%) groups, with low rates of hyperkalemia.

• 5

  The study faced limitations, including reliance on investigator-reported diagnoses and lack of biopsy confirmation for many participants.